15 October 2018

Designing Safer Medicines III

Organised by:

SCI's Fine Chemicals Group

London, UK

Synopsis

There is a clear need in drug development to reduce attrition from clinical studies especially due to toxicology. It was estimated that a 5-10% improvement in the attrition rate could double the output of marketed drugs. This meeting aims to provide practical insights into some of the recent preclinical approaches and strategies which have been developed to help the chemist design safer medicines. 


Attendees
This meeting is targeted at all those who are involved in the lead identification and lead optimisation processes in Drug Discovery and interested in furthering their knowledge of current and emerging approaches to designing safer Drug Candidates.
Programme
09.15 Registration and refreshments
09.45 Opening remarks
09.50 The impact of safety pharmacology assays at AstraZeneca within the "5R Framework"
Dr Peter Newham, AstraZeneca, UK
10.30 Challenges and opportunities for predicting developmental toxicity in new active substance research projects - a crop protection perspective
Dr Richard Currie, Syngenta, UK
11.10 Refreshment break
11.40 De-risking DILI using 3D liver microtissues
Dr Paul Walker, Cyprotex, UK
12.20 High dimensional profiling supporting early safety screening
Dr Hinrich Göhlmann, Janssen Pharmaceutica, Belgium
13.00 Lunch and exhibition
14.10 Designing safer oral glucocorticoid receptor modulators
Dr Lena Ripa, AstraZeneca, Sweden
14.50 Investigation of the mechanism of toxicity of a novel immuno-oncology agent
Dr Howard Mellor, Vertex Pharmaceuticals, UK
15.20 Refreshment break
15.50 Application of oral drug suitability parameters in designing safer drugs
Dr Mark Wenlock, InSilicoLynx Limited, UK
16.30 Data-driven drug and compound safety - using chemical and biological data to anticipate undesired effects
Dr Andreas Bender, University of Cambridge, UK
17.10 Closing remarks
17.15 Networking and refreshments

Venue and Contact

SCI

14/15 Belgrave Square
London
SW1X 8PS

Conference Team

Tel:+44 (0)20 7598 1561

Email: conferences@soci.org


Fees

Early bird fees before Monday 3 September 2018

One-Day Fee Two-Day Fee*
SCI Member £100 SCI Member £175
SCI Student Member £35 SCI Student Member £60
Non-Member £130 Non-Member £235

*The Two-Day Fee includes attendance at 'Designing Safer Medicines III' on Monday 15 October and 'Highlights in Medicinal Chemistry III' on Tuesday 16 October

Standard fees after Monday 3 September 2018

One-Day Fee Two-Day Fee*
SCI Member £115 SCI Member £205
SCI Student Member £40 SCI Student Member £70
Non-Member £150 Non-Member £270

*The Two-Day Fee includes attendance at 'Designing Safer Medicines III' on Monday 15 October and 'Highlights in Medicinal Chemistry III' on Tuesday 16 October

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations


Booking Process/Deadlines
For booking terms and conditions click here.
CPD Info

SCI Members attending this meeting are able to claim CPD points

sci cpd


Become an SCI Member to receive events discounts

Join SCI